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Abstract
Background
Major gaps in our understanding of Plasmodium vivax biology and the acquisition of immu-
nity to this parasite hinder vaccine development. P. vivaxmerozoites exclusively invade
reticulocytes, making parasite proteins that mediate reticulocyte binding and/or invasion
potential key vaccine or drug targets.While protein interactions that mediate invasion are
still poorly understood, the P. vivax Reticulocyte-Binding Protein family (PvRBP) is thought
to be involved in P. vivax restricted host-cell selectivity.
Methodology/Principalfindings
We assessed the binding specificity of five members of the PvRBP family (PvRBP1a,
PvRBP1b, PvRBP2a, PvRBP2b, PvRBP2-P2 and a non-binding fragment of PvRBP2c) to
normocytes or reticulocytes. PvRBP2b was identified as the only reticulocyte-specific
binder (P<0.001), whereas the others preferentially bound to normocytes (PvRBP1a/b
P0.034), or showed comparable binding to both (PvRBP2a/2-P2, P = 0.38). Furthermore,
we measured levels of total and IgG subclasses 1, 2, 3 and 4 to the six PvRBPs in a cohort
of young Papua New Guinean children, and assessed their relationship with prospective
risk of P. vivaxmalaria. Children had substantial, highly correlated (rho = 0.49–0.82,
P<0.001) antibody levels to all six PvRBPs, with dominant IgG1 and IgG3 subclasses. Both
total IgG (IncidenceRate Ratio [IRR] 0.63–0.73, P = 0.008–0.041) and IgG1 (IRR 0.56–
0.69, P = 0.001–0.035) to PvRBP2b and PvRBP1a were strongly associated with reduced
risk of vivax-malaria, independently of age and exposure.
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Conclusion/Significance
These results demonstrate a diversity of erythrocyte-binding phenotypes of PvRBPs, indi-
cating binding to both reticulocyte-specific and normocyte-specific ligands. Our findings pro-
vide further insights into the naturally acquired immunity to P. vivax and highlight the
importanceof PvRBP proteins as targets of naturally acquired humoral immunity. In-depth
studies of the role of PvRBPs in P. vivax invasion and functional validation of the role of anti-
PvRBP antibodies in clinical immunity against P. vivax are now required to confirm the
potential of the reticulocyte-binding PvRBP2b and PvRBP1a as vaccine candidate
antigens.
Author Summary
In parallel with the tremendous reduction in malaria burden, Plasmodium vivax (Pv) is
now the predominant malaria species in the Asia-Pacific and Americas. Pv can only invade
young erythrocytes (reticulocytes) and this restriction is thought to involve the Reticulo-
cyte-Binding Protein family (PvRBP). Given their predicted role, PvRBPs are potentially
interesting vaccine targets. However, the acquisition of immunity to Pv in general (PvRBPs
in particular) is poorly understood, hindering vaccine development. Here, we show that
out of five PvRBPs, only one (PvRBP2b) binds exclusively to reticulocytes.Furthermore,
we measured antibody levels to all six PvRBPs in a cohort of young Papua New Guinean
children, assessing the relationship between antibodies to PvRBPs and risk of malaria dis-
ease. Both total and specific antibody subclass levels (IgG1 and IgG3) to the reticulocyte-
specific binder PvRBP2b, and the non-specific binder PvRBP1a were strongly associated
with lower risk of clinical disease. Our findings indicate a diversity of roles of PvRBPs in
erythrocyte invasion and highlight their importance as targets of the naturally acquired
immunity to Pv. Functional studies of the role of PvRBPs in reticulocyte invasion will be
required to fully understand the potential of PvRBP1a and PvRBP2b as vaccine
candidates.
Introduction
The two major malaria parasites, Plasmodium falciparum and Plasmodium vivax, differ in
their ability to invade human erythrocytes.While P. falciparum invades both mature (normo-
cytes) and young erythrocytes (reticulocytes),P. vivax can only invade the latter [1]. This dif-
ferential specificity is believed to be mediated by distinct ligand-receptor interactions, though
the exact mechanisms remain to be elucidated [1]. For P. falciparum, the merozoite invasion of
erythrocytes is a multistep process [2] mediated by the binding of the erythrocytebinding-like
(EBL) and reticulocytebinding-like (PfRh) protein families to receptors on the surface of the
host cell [3]. For P. vivax, the only ligand-receptor interaction identified to date is between the
Duffy binding protein (PvDBP) and the Duffy antigen receptor for chemokines (DARC) [4].
The recently identified P. vivax erythrocyte-bindingprotein (PvEBP) also shares a Duffy bind-
ing-like domain [5]. However, the presence of DARC in both normocytes and reticulocytes
does not explain the restricted host-cell selectivity of P. vivax. The recent observation that P.
vivax can invade Duffy-negative cells also indicates the existence of alternative pathways of
invasion [6, 7].
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The P. vivax reticulocytebinding brotein family (PvRBP) is composed of 11 members [5, 8,
9], and although their precise roles remain largely unknown, their homology to the much better
characterized PfRh protein family suggests that they may be important invasion ligands [3].
Members of the PvRBP family have been implicated in erythrocytebinding, and in some cases
in reticulocyte recognition [8, 10]. Variation in expression of PvRBPs genes in different parasite
isolates have been described, suggesting that these genes may be redundant in function [11].
The relatively high degree of polymorphism observed in the genes encoding PvRBPs also indi-
cates that they are important for parasite survival and may be under immune selection [10, 12,
13]. Collectively, this suggests that the understudied PvRBP family may be of key importance
for P. vivax invasion, and like their better studied P. falciparum homologues, potential targets
for a vaccine targeting blood stage infections [14].
Antibodies to several P. vivaxmerozoite proteins have shown associations with reduced risk
of vivax-malaria in naturally exposed individuals [15]. Among them, antibodies to PvDBPs
have been target of extensive study [15]. While PvDBP is a promising vaccine candidate, sev-
eral challenges to vaccine development remain, including the presence of highly polymorphic,
immuno-dominant epitopes in the DARC-binding region II, and the need to elicit high titers
to achieve strain-transcending blocking [14]. It is therefore likely that PvDBP would need to be
combined with further antigens targeting alternative invasion ligands. Members of the PvRBP
family are recognizedby antibodies from vivax-positive patients [11, 16], and populations liv-
ing in endemic areas [17, 18]. Yet, an in-depth characterization of the immune responses to
these proteins, as well as the role of antibodies to PvRBPs in the acquisition of immunity to
malaria is lacking.
In this study, we have assessed the erythrocyte-bindingprofiles of five members of the
PvRBP family and their specificity to normocytes or reticulocytes, identifying a member of the
PvRBP family that exclusively binds to reticulocytes. Furthermore, we measured levels of total
and IgG subclasses to these five PvRBPs and a non- erythrocytebinding protein fragment of a
sixth PvRBP in a cohort of young Papua New Guinean (PNG) children with well-characterized
differences in exposure.We identified an association between reduced risk of vivax-malaria
and antibodies to two of the PvRBPs, including the reticulocyte-specificbinder. Our results
provide important insights into the acquisition of immunity to PvRBPs in young children,
highlighting this protein family as an interesting target to be further evaluated for their poten-
tial as P. vivax vaccine antigens.
Methods
PvRBPs expression and purification
Proteins included in this study were PvRBP1a (amino acids [aa] 160–1170), PvRBP1b (aa 140–
1275), PvRBP2a (aa 160–1135), PvRBP2b (aa 161–1454), PvRBP2cNB (aa 501–1300) and
PvRBP2-P2 (aa 161–641) Their expression and purification have been described in details else-
where [10, 11]. Despite several attempts, we were unsuccessful in expressing recombinant
PvRBP2c that includes the conserved erythrocyte-bindingdomain in E. coli using both native
and refolding methods. Thus, the PvRBP2cNB fragment included in this study does not con-
tain the erythrocyte-bindingdomain, which encompasses residues 128 to 429. An SDS-PAGE
of PvRBP2-P2 recombinant protein is shown in S1 Fig; the purity and stability of the remaining
PvRBPs have been verified and presented in a previous publication [11].
Polyclonal rabbit anti-PvRBP antibody production
Antibody production was performed at theWalter and Eliza Hall Institute Monoclonal Anti-
body Facility as previously described [10].
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Screening of rabbit anti-PvRBP IgG by enzyme-linked immunosorbent
assay (ELISA)
96-well flat-bottomed plates (Maxisorp, Nunc) were coated with each of the 6 PvRBPs (65 nM/
well) in individual wells and incubated for two hours. For 65 nM of protein in 100 μL, we
added 0.8 μg, 0.9 μg, 0.7 μg, 1 μg, 0.6 μg and 0.4 μg for PvRBP1a, PvRBP1b, PvRBP2a,
PvRBP2b, PvRBP2cNB and PvRBP2_P2 respectively. Plates were blocked with 5% skimmilk/
0.1% Tween-20 for one hour. After washing, specific anti-PvRBP polyclonal antibodies (1 mg/
mL stock) were added at halving serial dilutions (from 1:2000 to 1:64000) for one hour. Plates
were washed three times before the addition of HRP-goat anti-rabbit secondary antibodies
(1:2000 dilution) for one hour. Azino-bis-3-ethylbenthiazoline-6-sulfonic acid (ABTS liquid
substrate; Sigma-Aldrich) was used to detect HRP activity. 1% SDS was used to stop the reac-
tion and absorbance was measured at 405 nm. All experiments were performed at room tem-
perature. All washes were done in PBS/0.1% Tween-20, and dilutions of antibodies in 0.5%
skimmilk/0.1%Tween-20. Samples were tested in duplicates.
Flow cytometry-basederythrocyte-bindingassay
Reticulocyteswere enriched from whole blood and the erythrocyte-bindingassays performed
as describedpreviously [10]. Binding of PvRBPs was detected using 0.025 mg/mL of corre-
sponding anti-PvRBP rabbit IgG.
Study population
Antibody reactivity to the 6 PvRBPs in naturally-exposed individuals was assessed in samples
from a longitudinal cohort of 264 children (1–3 years old) undertaken in Ilaita, East Sepik
Province, PNG [19]. Children were enrolled betweenMarch-September 2006, and followed for
up to 16 months. Blood samples were collected every eight weeks and at episodes of febrile ill-
ness. All P. vivax infections were genotyped, allowing the determination of the incidence of
genetically distinct blood-stage infections acquired during follow-up (i.e. the molecular force of
blood-stage infections, molFOB) [20]. Samples collected at enrolment from 224 children that
completed follow-up were included in the present study (median age 1.7, inter-quartile range
[IQR] 1.3–2.5).
Protein conjugation and antibodymeasurement
To measure antibody levels in the cohort of PNG children, purified proteins were conjugated
to Luminex Microplex microspheres (Luminex Corp.) as described elsewhere [21, 22], using
the following concentrations per 2.5 x 106 beads: PvRBP1a = 3 μg/mL; PvRBP1b = 11.4 μg/mL;
PvRBP2a = 6.7 μg/mL; PvRBP2b = 0.2 μg/mL; PvRBP2cNB= 0.8 μg/mL; PvRBP2-P2 = 5.4 μg/mL.
Bead-array assays were performed as previously described [23]. Plasma samples were
diluted 1:50 in PBS, and secondary antibody donkey F(ab’)2 anti-human IgG Fc R-PE (1 mg/
mL, Jackson Immunoresearch); mouse anti-human IgG1 hinge-PE (0.1 mg/ mL, clone 4E3,
Southern Biotech); IgG2 Fc-PE (0.1 mg/ mL, clone HP6002, Southern Biotech); IgG3 hinge-PE
(0.1 mg/ mL clone HP6050, Southern Biotech); or IgG4 Fc-PE (0.1 mg/ mL, clone HP6025,
Southern Biotech) diluted 1:100 in PBS was added to detect total, IgG1, IgG2, IgG3 or IgG4
respectively. A dilution series of a pool made of serum collected as part of an earlier study with
immune adults living in different villages of high malaria transmission in East Sepik Province,
PNG, was included on each plate as positive controls.
IgGResponses to PvRBPs and Protection against P. vivaxMalaria
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Statistical analysis
To correct plate-to-plate variations, the dilutions of the PNG adult pool were fitted as plate-
specific standard curves using a 5-parameter logistic regression model [22, 24]. For each plate,
median fluorescence intensity (MFI) values were interpolated into relative antibody units
based on the parameters estimated from the plate’s standard curve.
Associations with age, exposure and correlations between antibody levels of different sub-
classes and/or different antigens were determined using Spearman’s rank correlation, and dif-
ferences by infection status using Mann-Whitney U tests. Generalized estimating equation
(GEE) models with exchangeable correlation structure and semi-robust variance estimator
were used to analyze the relationship between antibodies to PvRBPs and prospective risk of P.
vivax episodes (defined as axillary temperature 37.5°C or history of fever in preceding 48
hours with a concurrent parasitaemia>500 P. vivax parasites/μl) over the 16 months of fol-
low-up [22, 25]. For this, antibody levels were classified into tertiles (cut-off values are shown
in Table 1), and analyses were done comparing the incidence rate ratio (IRR) of clinical malaria
Table 1. Total and IgG subclass reactivity to PvRBPs in young Papua NewGuineanchildren.
PvRBP1a PvRBP1b PvRBP2a PvRBP2b PvRBP2cNB PvRBP2-P2
Total
IgG
IgG1 IgG3 Total
IgG
IgG1 Total
IgG
IgG1 IgG3 Total
IgG
IgG1 Total
IgG
IgG1 Total
IgG
IgG1 IgG3
Level* in children (% of adult levels)
Median 0.0025
(12.3)
0.0051
(25.5)
0.0002
(0.85)
0.0019
(9.6)
0.0054
(27.0)
0.0035
(17.3)
0.0037
(18.5)
0.0002
(0.91)
0.0029
(14.4)
0.0067
(33.4)
0.0006
(3.0)
0.0011
(5.3)
0.0095
(47.4)
0.0057
(28.5)
0.0031
(15.5)
IQR 0.0010
(5.1)
0.0025
(12.5)
0.0001
(0.32)
0.0010
(5.0)
0.0033
(16.3)
0.0013
(6.7)
0.0011
(5.7)
0.0001
(0.46)
0.0013
(6.5)
0.0024
(11.8)
0.0003
(1.5)
0.0005
(2.7)
0.0041
(20.5)
0.0025
(12.7)
0.0012
(5.8)
0.0053
(26.3)
0.0094
(46.8)
0.0006
(3.1)
0.0041
(20.4)
0.0105
(52.3)
0.0101
(50.4)
0.0132
(65.8)
0.0005
(2.8)
0.0059
(29.6)
0.0149
(74.6)
0.0015
(7.7)
0.0025
(12.7)
0.0181
(90.1)
0.0128
(64.1)
0.0079
(39.7)
Cut-off*
low
antibody
levels
0.0013
(6.3)
0.0031
(15.6)
0.0001
(0.47)
0.0013
(6.4)
0.0039
(19.7)
0.0017
(8.6)
0.0017
(8.5)
0.0001
(0.56)
0.0019
(9.6)
0.0037
(18.5)
0.0004
(2.0)
0.0007
(3.4)
0.0056
(27.9)
0.0033
(16.8)
0.0016
(7.9)
Cut-off*
medium
antibody
levels
0.0038
(19.0)
0.0077
(38.5)
0.0004
(2.0)
0.0029
(14.5)
0.0078
(39.2)
0.0074
(36.9)
0.0086
(43.1)
0.0003
(1.7)
0.0046
(23.0)
0.0119
(59.7)
0.0010
(5.10)
0.0018
(9.1)
0.0145
(72.3)
0.0107
(53.4)
0.0053
(26.4)
Cumulative prevalence in
children, n (%)
% of adult
levels
(antibody
cut-off
value *)
1%
( 0.0002)
221
(98.7)
224
(100.0)
106
(47.3)
222
(99.1)
224
(100.0)
222
(99.1)
218
(97.3)
107
(47.8)
223
(90.6)
223
(99.6)
190
(84.8)
214
(95.5)
224
(100.0)
223
(99.6)
215
(96.0)
5%
( 0.001)
169
(75.5)
216
(96.4)
34
(15.2)
169
(75.5)
218
(97.3)
182
(81.2)
174
(77.7)
23
(10.3)
181
(80.8)
211
(94.2)
77
(34.4)
115
(51.3)
223
(99.6)
209
(93.3)
175
(78.1)
10%
( 0.002)
127
(56.7)
184
(82.1)
16
(7.1)
109
(48.7)
208
(92.9)
139
(62.1)
139
(62.1)
9 (4.0) 147
(65.6)
177
(79.0)
45
(20.1)
67
(29.9)
212
(94.6)
186
(83.0)
142
(63.4)
25%
( 0.005)
57
(25.5)
114
(50.9)
3 (1.3) 49
(21.9)
123
(54.9)
94
(42.0)
104
(46.4)
0 (0.0) 65
(29.0)
135
(60.3)
27
(12.1)
33
(14.7)
158
(70.5)
119
(53.1)
77
(34.4)
50%
( 0.01)
28
(12.5)
46
(20.5)
1
(0.45)
17
(7.6)
57
(25.5)
56
(25.0)
67
(29.9)
0 (0.0) 22
(9.8)
83
(37.1)
15
(6.7)
19
(8.5)
105
(46.9)
80
(35.7)
46
(20.5)
Abbreviations: IQR = Interquartile range
*Values in arbitraryunits. Values were interpolated from standard curves using a 5PL logistic regressionmodel.
doi:10.1371/journal.pntd.0005014.t001
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in those with medium and high versus low antibody levels. Children were considered at-risk
from the first day after the blood sample for active follow-up was taken. For each child, the
molFOB was calculated as the number of new blood-stage genetically distinct P. vivax clones
acquired/year-at-risk, and square-root transformed for better fit [20]. Adjustments were made
for seasonal trends, village of residency, age, and molFOB. In order to study the breadth of
anti-PvRBP antibodies, for each antigen antibody levels stratified into tertiles were scored as 0
for low, 1 for medium and 2 for the high tertiles, respectively. Scores were then added up to
reflect the breadth of anti-RBP antibodies, yielding a median score of 6 (IQR 2–9).
All analyses were performed using STATA version 12 (StataCorp) or R version 3.2.1 (http://
cran.r-project.org).
Ethics statement
Ethical clearance was obtained from the PNGMedical Research and Advisory Committee
(MRAC 05.19), and theWalter and Eliza Hall Institute (HREC 07/07). Written informed con-
sent was obtained from the parents or guardians all children participating in the cohort study.
Results
Erythrocyte-binding characteristicsof PvRBPs
Except for the PvRBP2cNB fragment, all PvRBPs proteins expressed encompass the conserved
erythrocyte-bindingdomain [10]. As such, PvRBP2cNB binding serves as a control for back-
ground signal in this flow cytometry-basedassay. Binding was significantly higher for all bind-
ing fragments except for PvRBP2b in normocytes (not stained with thiazole orange, TO-) and
PvRBP1b in reticulocyes (stained with thiazole orange, TO +) (both P>0.05). Among the five
binding PvRBPs tested we found three types of binding profiles: i) binding preferentially to
normocytes: PvRBP1a (Fig 1, TO- vs. TO+: P = 0.034) and PvRBP1b (P = 0.017); ii) binding to
Fig 1. Erythrocyte-bindingpreferences of 6 PvRBPs.A: Bar charts showing the percentageof binding of CD71-PECy5 (control),
PvRBP1a, PvRBP1b, PvRBP2a, PvRBP2b, PvRBP2cNB, PvRBP2-P2 to mature erythrocytes(not stainedwith thiazole orange, TO-)
vs reticulocytes (stainedwith thiazole orange, TO+) populations. Error bars represent SEM of 7 or 9 independent repeats. B: Dot plots
show the binding of six PvRBP proteins to an enriched reticulocyte population. Binding was detected using an anti-PvRBP rabbit IgG
antibody followed by a secondary anti-rabbit Alexa 647 antibody.
doi:10.1371/journal.pntd.0005014.g001
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both normocytes and reticulocytes:PvRBP2a (P = 0.38) and PvRBP2-P2 (P = 0.38); and iii)
binding only to reticulocytes:PvRBP2b (P< 0.001).
IgG to PvRBPs in young children
We assumed that the pooled serum from hyper-immune PNG adults represented the equilib-
rium antibody levels to all proteins achievable under life-long natural exposure. Therefore, by
comparison with IgG levels observed in PNG children, we determined how many children
have already achieved IgG levels that were>50%,>25% or>10% of the adult levels (Table 1).
Although, semi-immune, young PNG children were reactive to all six PvRBPs tested, there
were differences in the immunogenicity of different proteins (Table 1; S2 Fig). Whereas, 47%
and 95% of children had reached>50% and>10% of the hyper-immune adult levels for
PvRBP2-P2, respectively, only 7% and 20% reached the same levels for antibodies targeting the
non-red cell binding PvRBP2cNB fragment (P< 0.001). The other proteins were intermedi-
ately immunogenic, with antibodies to PvRBP2a more rapidly acquired than those to
PvRBP2b, PvRBP1a and PvRBP1b (Table 1; S2 Fig). To each PvRBP, total IgG levels correlated
moderate to strongly with IgG levels to the other PvRBPs (rho = 0.49–0.82, P< 0.001), with
the strongest correlation between PvRBP1b and PvRBP2b (rho = 0.82) (S1 Table).
Rabbit polyclonal antibodies against the different PvRBP constructs showed strong recogni-
tion of the specific constructs but only limited cross-reactivity (Fig 2). The exception was anti-
bodies raised against the PvRBP2cNB fragment, which showed low cross-reactivity with
PvRBP1b and PvRBP2a. This indicated that the high correlations in naturally acquired total
IgG levels are therefore likely to reflect co-acquisition rather than cross-reactivity (Fig 2).
Influence of age, current and cumulative malaria exposure on IgG to
PvRBPs
While antibodies to PvRBP1a, PvRBP1b, PvRBP2b and PvRBP2cNB increasedmoderately
with age (rho = 0.15–0.29, P< 0.001–0.025), no such association was found for the two most
immunogenic proteins, PvRBP2a and PvRBP2-P2 (Fig 3A; S2 Table). Total IgG levels to all
proteins except PvRBP1b were significantly higher in the 124 children (55.4%) that had a cur-
rent, PCR-detectable P. vivax infection (P< 0.001–0.006) (S2 Table). To better understand the
effect of age on the acquisition of antibodies to PvRBPs, we stratified children by the presence
of infection at sample collection.After stratification, increase in total IgG to PvRBP1b,
PvRBP2b, PvRBP2cNB and PvRBP2-P2 with age were stronger in children with current infec-
tion (rho = 0.19–0.33, P< 0.001–0.039) suggesting that antibodies to PvRBPs are strongly
reflective of recent exposure (S2 Table).
Given the young age and large heterogeneity in exposure among children [20], age is not a
good proxy for life-time exposure. As a better measure of life-time exposure to malaria, we
therefore calculated the molFOB (described in methods) [20]. This estimated P. vivax life-time
exposure was a substantially better predictor of antibody levels than age, and total IgG levels to
all 6 PvRBPs significantly increasedwith increasing life-time exposure (rho = 0.18–0.36,
P< 0.001–0.006) (Fig 3B; S2 Table). For PvRBP1a and PvRBP2a, the effect of life-time expo-
sure to P. vivaxwas observedonly in children free of infection at study start (P = 0.008–0.022),
again indicating that the effect of recent infections on antibodies to PvRBPs is strong (Fig 3C;
S2 Table).
The breadth of anti-PvRBP antibodies (described in methods) was higher in children with
concurrent P. vivax infection (median in children free of infection = 4.5, IQR = 2–8 versus
median in infected children = 7, IQR = 4–10; P< 0.001), and increasedwith increasing esti-
mated life-time exposure (rho = 0.29, P< 0.001).
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IgG subclasses to PvRBPs
In hyper-immune PNG adults, four different patterns of IgG subclass reactivity to PvRBPs
were observed i) predominant IgG1 with sub-dominant IgG3: PvRBP2-P2; ii) predominant
IgG3 with sub-dominant IgG1: PvRBP1a; iii) predominant IgG1 with sub-dominants IgG2
+IgG3: PvRBP2a, PvRPB2b and PvRBP2cNB; and iv) IgG1+IgG2+IgG3 with no obvious domi-
nance: PvRBP1b. There were no detectable levels of IgG4 to any of the proteins (Table 1; S3
Fig).
In comparison to adults, young children had already acquired substantial IgG1 levels to all 6
PvRBPs. Apart from the less immunogenic PvRBP2cNB fragment,>20% and>62% of the
Fig 2. Detectionof PvRBPs by rabbit anti-PvRBPpolyclonal antibodiesby ELISA.Microtiter wells were
coated with each PvRBP per well as shown by symbols on the left. Solid lines show specific anti-PvRBPs
polyclonal antibodies (top label) added to each plate in a dilution series. The optical density (OD)was measuredat
405 nm.MeanOD values from duplicatedwells and standard deviation are shown.
doi:10.1371/journal.pntd.0005014.g002
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children had reached>50% and>10% of the IgG1 levels seen in hyper-immune adults to the
different PvRBPs. PvRBP1a, PvRBP2-P2 and PvRBP2a also had detectable levels of IgG3, but
only PvRBP2-P2 had a similarly high prevalence of IgG3 as for IgG1 (20.5% and 63.4%, respec-
tively) (Table 1; S3 Fig), indicating that IgG1 antibodies were acquired faster than IgG3. The
predominance of IgG1 subclass is further highlighted by the generally stronger correlations of
total IgG with IgG1 (rho = 0.91–0.94, P< 0.001) than IgG3 (rho = 0.55–0.71, P< 0.001) (S1
Table). Despite the narrow age group in the cohort, there was a weak indication of polarization
towards IgG3 with increasing age to PvRBP1a (rho = -0.19, P = 0.005) and PvRBP2-P2 (rho =
-0.16, P = 0.015), evidenced as a decrease in the IgG1/IgG3 ratio. Children had no detectable
IgG2 or IgG4 to any of the proteins (S3 Fig).
IgG1 to all 6 PvRBPs (P 0.003) were higher in infected children, although only moderately
to PvRBP1b and PvRBP2cNB (P = 0.06). Similarly, those with a current infection had higher
IgG3 to PvRBP1a, PvRBP2a and PvRBP2-P2 (P 0.002) (S2 Table). For the PvRBPs with
dominant IgG1 subclass, the effect of age and exposuremostly mimic that observed for total
IgG (S2 Table). For PvRBP2-P2 and PvRBP1a IgG3, but not IgG1, still increasedwith age
(rho = 0.19–0.21, P = 0.002–0.005) (S2 Table).
IgG to PvRBPs and protection against symptomaticmalaria
Over the 16 months follow-up of the PNG cohort, each child had an incidence rate of 1.25
(95%CI 1.08–1.45) P. vivax episodes/year at risk. Following adjustment for confounders, total
IgG to all 6 PvRBPs tested were associated with protection against P. vivaxmalaria (IRR 0.52–
0.69, P< 0.001–0.016) (Fig 4; S3 Table).
To further understand the contribution of antibodies to specific PvRBPs in the protective
effect observed,we fitted a multivariate model to account for the fact that antibodies to the 6
PvRBPs were co-acquired and therefore highly correlated. In multivariate analysis, only total
IgG to PvRBP1a (IRRM 0.71, 95%CI 0.53–0.94, P = 0.019; IRRH 0.63, 95%CI 0.44–0.88,
P = 0.008), and PvRBP2b (IRRM 0.73, 95%CI 0.54–0.99, P = 0.041; IRRH 0.63, 95%CI 0.44–0.90,
P = 0.011) remained associated with reduced risk of vivax-malaria, suggesting that antibodies
to these two PvRBPs are important correlates of naturally-acquired protective immunity.
IgG subclasses to PvRBPs and protection
After adjusting for confounders, both IgG1 and IgG3 to PvRBP1a (IgG1 IRR 0.48, P< 0.001;
IgG3 IRR 0.51–0.67, P< 0.001–0.011) and PvRBP2a (IgG1 IRR 0.66, P = 0.010; IgG3 IRR 0.51,
P< 0.001–0.011), and only IgG3 to PvRBP2-P2 (IRR 0.60, P = 0.002) were associated with
reduced risk of vivax-malaria. IgG1 to PvRBP1b (IRR 0.52, P< 0.001) and PvRBP2b (IRR
057–0.59, P< 0.001) was also associated with protection. No association was found for the
non-binding PvRBP2cNB fragment, although it was observed for total IgG levels in univariate
analysis (Fig 4; S3 Table).
In a model combining both IgG1 and IgG3 levels to a given antigen, both IgG1 and IgG3
remained significantly associated with protection for PvRBP1a (IgG1 IRRH 0.55, 95%CI 0.38–
0.80, P = 0.001; IgG3 IRRM 0.69, 95%CI 0.51–0.92, P = 0.011), and only IgG3 for PvRBP2a
Fig 3. Association between total IgG to 6 PvRBPs age and exposure in 224 young Papua NewGuinea
children.A & B: Data are plotted as Lowess smoothed curves of total IgG levels (arbitrary units) by age and
life-time exposure respectively. Life-time exposure was calculated as agemultiplied by molFOB. Correlation
coefficients (rho) and P-values fromSpearman’s rank test.C: Boxplots showmedian total IgG levels (arbitrary
units) and range (whiskers) by infection status detected by PCR. Clear boxes show low antibody levels, dotted
boxes showmediumantibody levels and grey boxes show high antibody levels. P-values fromKruskal-Wallis
test. For all analysis, P < 0.05 were deemed significant.
doi:10.1371/journal.pntd.0005014.g003
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(IRRH 0.51 0.36–0.72, P< 0.001) and PvRBP2-P2 (IRRH 0.60, 95%CI 0.43–0.84, P = 0.002).
When combining IgG1 and IgG3 to all PvRBPs in a multivariate model, however, only IgG1 to
PvRBP1a (IRRH 0.56, 95%CI 0.39–0.80, P = 0.001) and PvRBP2b (IRRM 0.64, 0.46–0.90,
P = 0.011; IRRH 0.69, 95%CI 0.48–0.97, P = 0.035) remained associated with reduced risk of
vivax-malaria.
Anti-PvRBP antibody repertoireand risk of vivax-malaria
There was a very strong association between increasing total IgG to the repertoire of PvRBPs,
and increase in protection against vivax-malaria. For each increase in one unit of the breadth
score (see methods for detailed description), a reduction of approximately 8% in the incidence
rate of P. vivax episodes was observed (IRR 0.92, 95%CI 0.89–0.96, P< 0.001). Considering the
repertoire of IgG1 antibodies, the reduction in risk was of approximately 7% (IRR 0.93, 95%CI
0.90–0.97, P< 0.001). The effect of the IgG1 repertoire is no longer significant after IgG1 to
PvRBP1a (IRRH 0.53, 95%CI 0.33–0.85, P = 0.008) and PvRBP2b (IRRM 0.63, 95%CI 0.44–0.89,
P = 0.010, IRRH 0.65, 95%CI 0.42–1.00, P = 0.053) is accounted for, again highlighting impor-
tance of these proteins in naturally-acquired protective immunity.
Discussion
Advances in understanding P. vivax biology and the acquisition of immunity to this parasite,
as well as the development of vaccines against P. vivax lag much behind what has been achieved
for P. falciparum [14, 26, 27]. This is largely due the lack of a stable in vitro culture system for
P. vivax that makes functional studies very challenging.
In this study, we investigated whether six recombinantly expressed members of the PvRBP
family are involved in P. vivax host-cell specificity by testing their erythrocyte-bindingprefer-
ences.We identified that only PvRBP2b binds solely to reticulocytes. In previous reports,
PvRBP1a and PvRBP2c have also been described as reticulocyte-specificbinders [8]. Our
recombinant PvRBP1a however binds preferentially to normocytes.One explanation for this
observation is that C-terminal regions outside of the recombinant construct that is present on
native protein governs reticulocyte specificity. In addition, PvRBP1a forms a complex with
PvRBP2c [8] in parasites and this complex may be responsible for reticulocyte-binding.
Fig 4. Associationbetween total and IgG subclasses to 6 PvRBPs and protection against clinicalmalaria (density> 500/μL) in 224
young Papua NewGuinean children.Data are plotted as exposure (molFOB), age, season and village of residency adjusted incidence
rate ratios and 95% confidence intervals. Incidence rate ratios, 95% confidence intervals and P-values fromGEEmodels. P < 0.05 were
deemed significant. ****P < 0.001; ***P = 0.001; ** P > 0.001 to 0.01; *P > 0.01 to 0.05.
doi:10.1371/journal.pntd.0005014.g004
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Unfortunately, as we were unsuccessful in expressing recombinant PvRBP2c with its binding
domain, we were unable to confirm its erythrocyte-bindingprofile. The molecularmechanisms
by which PvRBP2bmediates specific reticulocytebinding, and its reticulocyte-specificreceptor
are yet to be elucidated.
Since our ability to do functional assays with P. vivax is constrained due to the lack of in
vitro culture, we sought to investigate whether antibodies to the 6 PvRBPs are targeted by natu-
ral-immunity in a population of young children from PNG. The 6 PvRBPs were recognizeddif-
ferently. The PvRPB2cNB fragment had the lowest immunogenicity of all and antibodies to
this fragment did not have a strong association with risk of vivax-malaria. This may be a conse-
quence of the absence of the erythrocyte-bindingregion. The strongest protective effect was
observed for total IgG to PvRBP1a and PvRBP2b. As there is poor cross-reactivity between
antibodies targeting the binding regions of different PvRBPs, it is highly likely that these anti-
bodiesmay have additive or even synergistic effects.
IgG1 and IgG3 were the predominant IgG subclass to PvRBPs in PNG children. Interest-
ingly, the dominant IgG subclass to PvRBP1a was different between children (IgG1) and adults
(IgG3). For PvRBP1a and PvRBP2-P2, there was also some early evidence of switching to IgG3
with increasing age. Exposure to malaria parasites, among other antigenic and host characteris-
tics, seems to play a major role in determining the predominant IgG response and for P. falcip-
arummerozoite antigens, both age and transmission intensity have been previously associated
with switching in predominance of the IgG subclass towards IgG3 [28, 29]. Both IgG1 and
IgG3 subclasses are cytophilic, T-cell dependent, and bind strongly to Fcγ, mediating phago-
cyte activation and complement fixation [30, 31], and predominance of IgG1 and/or IgG3, in
variable ratios, is common for several P. vivax [32–34] and P. falciparum merozoite proteins
[35–37]. For the young PNG children included in this study, a reduction in risk of vivax-
malaria was observedwith IgG3 to PvRBP1a, PvRBP2a and PvRBP2-P2 but, ultimately, it was
IgG1 to PvRBP1a and PvRBP2b that showed the strongest associations with protection. Adults
also had detectable levels of non-cytophilic IgG2 to most PvRBPs tested however, the signifi-
cance of this finding remains to be investigated. In P. falciparum IgG2 antibodies to EBA175
were shown to be short-lived [38], but nevertheless correlated with lower parasitemia. High
levels of IgG2 to RESA and MSP2 have also been associated with a lower risk of P. falciparum
infection [39], indicating that although uncommon, IgG2 antibodiesmight be important for
immunity against malaria.
Antibodies to PvRBP2b have also been previously associated with lower parasitaemia in
clinical cases [11]. Both proteins seem to be under selective pressure and, in comparison to
PvRBP1a, PvRPB2b is less polymorphic and with highly conserved regions, which may be ben-
eficial for vaccine development [12, 13]. Both PvRBP1a and PvRBP2b are less genetically
diverse than PvRBP2c [12, 13]. The existence of antigenic diversity in the different PvRBP
genes however, has never been investigated. A study with Brazilian samples identified two
regions of PvRBP1a (aa 431–748 and 733–1407) as the most immunogenic with predominant
IgG1 response, but the relationship between antibodies to the different regions and protection
was not explored [18]. Further studies of different regions of both PvRBP1a and PvRBP2bmol-
ecules would be important to identify the main epitopes targeted by protective antibodies.
The major limitation of this study is the lack of inclusion of a recombinant protein contain-
ing the binding domain of PvRBP2c, precluding both the investigation of the red-cell binding
characteristics of PvRBPc and determining relative importance of antibodies targeting red-cell
binding fragments of all main PvRBP proteins. Nevertheless, this is the first study where anti-
body levels to PvRBPs were investigated in samples from a well-designed longitudinal cohort
study, which made it possible to adjust for other factors that confound the relationship between
antibody acquisition and risk of disease,most importantly the heterogeneity in individual
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exposure to P. vivax blood stage infections [20]. The findings of this study provide further
insight into P. vivax host-specificity and naturally-acquired immunity to PvRBPs in children.
While the molecular functions of PvRBPs in P. vivax invasion are not well understood, the
role of the PfRh family, which are homologs of PvRBPs in P. falciparum, have beenwell charac-
terized in parasite invasion [3]. Severalmembers of the PfRh family have been implicated in rec-
ognition of red blood cells, signaling events or creating a pore in the red blood cell membrane
during invasion [40–44]. In particular PfRh5 has been a focus of intense research as a leading
blood stage vaccine candidate due to its essential function in P. falciparum invasion [45, 46].
Apart from gene structure and sequence homology, PvRBP2a and PfRh5 also adopt a similar
structural fold within their erythrocyte-bindingdomains [10, 47, 48]. Using this structural scaf-
fold with varied surface properties PvRBPs and PfRhs are able to mediate alternate receptor
engagement. Monoclonal antibodies against PfRh5 results in the strong inhibition of parasite
growth across multiple strains and Aotus nancymaaemonkeys immunizedwith anti-PfRh5 vac-
cine are protected against severe infection [42, 49, 50]. It is likely that the erythrocyte-binding
domain of PvRBPs will be able to elicit antibodies that have the ability to block P. vivax invasion.
Our results underline the key role of PvRBPs in parasite–host interactions and highlight
their potential as P. vivax vaccine candidate antigens. Further immuno-epidemiological studies
in broader age groups from areas of different transmission intensities, as well as functional
studies in vitro or in animal models, and a better understanding the molecular function of all
PvRBPs, including the PvRBP1a/PvRBP2c complex in P. vivax invasion are now required to
validate and prioritize one or several PvRBPs for development as vaccine candidates.
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